DMAC
DiaMedica Therapeutics Inc
Halal Rating :
Last Price
$5.76
Last updated:
Market Cap
-
7D Change
16.13%
1 Year Change
106.45%
Company Overview
Industries
Exchange
Next Earnings Date
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases. Their lead product candidate is DM199, a recombinant form of human tissue kallikrein-1 (KLK1) protein, which is in development for the treatment of acute ischemic stroke and chronic kidney disease.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate DiaMedica Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.